A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 36, Issue 7, 2006, Pages 410-417

  Hyodo, Ichinosuke ^a   Shirao, Kuniaki ^b   Doi, Toshihiko ^c   Hatake, Kiyohiko ^d   Arai, Yasuaki ^b   Yamaguchi, Kensei ^e   Tamura, Takao ^f   Takemiya, Shoji ^g   Takiuchi, Hiroya ^h   Nakagawa, Kazuhiko ⁱ   Mishima, Hideyuki ^j  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

^h OSAKA MEDICAL COLLEGE   (Japan)

ⁱ KINKI UNIVERSITY   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

Capecitabine; Colorectal cancer; Phase II study

Indexed keywords

CAPECITABINE; DRUG METABOLITE; FLUOROURACIL; FLUOROURACIL DERIVATIVE;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLISTER; BLOOD ANALYSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSESTHESIA; ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HEPATITIS C; HUMAN; HYDRONEPHROSIS; HYPERGLYCEMIA; ILEUS; JAPAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; RETREATMENT; STOMATITIS; SURVIVAL TIME; SWELLING; TREATMENT DURATION; ULCER; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECTAL NEOPLASMS;

EID: 33748118471     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl058     Document Type: Article

References (21)

1. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-15.
2. Anon. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16:301-8.
3. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15: 110-5.
4. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and. pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58.
5. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34: 1274-81.
6. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091-7.
7. Saeki T, Takashima S, Terashima M, Satoh A, Toi M, Osaki A, et al. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Int J Clin Oncol 2005;10:51-7.
8. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with Capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-85.
9. Kondo Y, Terashima M, Sato A, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer. Jpn J Clin Oncol 2004;34:195-201.
10. Sakamoto J, Kondo Y, Takemiya S, Sakamoto N, Nishisho I, on behalf of the clinical study group of capecitabine. A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. Anti-Cancer Drugs 2004;15:137-43.
11. Twelves C. Capecitabine as fast-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 2002;38(Suppl. 2):15-20.
12. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75.
13. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004;90:1190-7.
14. Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: Results of an extended phase I study. Ann Oncol 2003;14:1442-8.
15. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in fast-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 2005;16:282-8.
16. Diaz-Rubio E, Evans TR, Tabernero J, Cassidy J, Sastre J, Eatock M, et al. Capecitabine (Xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-65.
17. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (Capecitabine Plus Oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
18. Fernando N, Yu D, Morse M, Blobe G, Odogwu L, Crews J, et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 2005;23:6S(Abst. 3556).
19. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000;92: 205-16.
20. National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, April 30, 1999).
21. Reigner B, Watanabe T, Schuller J, Lucraft H, Sasaki Y, Bridgewater J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52:193-201.